Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, controlled trial with 50 veterans diagnosed with post-traumatic stress
disorder (PTSD) and comorbid alcohol dependence. Veterans will be randomized to receive
either zonisamide (400 mg) or placebo for 12 weeks in a double blind fashion. Randomization
will be done using 3:1 ratio and will be performed by our research pharmacy using a random
assignment in blocks of 4- 3 will be assigned to active medication and 1 to placebo.
Medication will be titrated over a 6 week titration phase followed by a 6 week treatment
phase. All veterans will receive E-CPT-C therapy for the 12 weeks of treatment; E-CPT-C will
be provided by trained and qualified clinicians with extensive experience providing E-CPT-C.
Veterans will be recruited primarily through advertisement, but also through the clinical
facilities at the VA and from other collaborators.